• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine

tetano

Editor, Senior Moderator
Curr Opin Virol. 2016 Mar 28;17:110-115. doi: 10.1016/j.coviro.2016.03.002. [Epub ahead of print]
[h=1]Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.[/h] Cho A[SUP]1[/SUP], Wrammert J[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Serum antibodies are the major correlate of influenza vaccine efficacy, providing short-term protection against infection. Recent efforts have been focused on studying antibody responses at a monoclonal level to understand their role in protection against influenza, and to ultimately improve vaccine strategies to provide broader, long-term immunity against influenza virus. These studies have shown that broadly neutralizing antibodies specific for the conserved stem domain of the hemagglutinin protein can target multiple strains of influenza. These antibodies show great promise both from a therapeutic perspective as well as for guiding vaccine design efforts. In this review, we will summarize past and recent findings about broadly neutralizing antibodies against influenza, and discuss how these findings may guide development of universal vaccine strategies.
Copyright ? 2016 Elsevier B.V. All rights reserved.


PMID: 27031684 [PubMed - as supplied by publisher]
 
Back
Top Bottom